Halozyme Therapeutics, Inc. reported significant financial growth in its latest quarterly results, with total revenues reaching $481.0 million for the three months ended June 30, 2026, a 47% increase from $325.7 million in the same period last year. The surge in revenue was primarily driven by a 50% rise in royalties, which amounted to $307.7 million, up from $205.6 million. Product sales also saw a notable increase, climbing 59% to $129.6 million, largely due to heightened demand for bulk rHuPH20 and proprietary products like XYOSTED. The company’s net income for the quarter was $229.9 million, translating to earnings per share of $1.96, compared to $165.2 million and $1.36 per share in the prior year.
In comparison to the previous fiscal period, Halozyme's financial performance showed marked improvement. For the first half of 2026, total revenues were $857.7 million, a 45% increase from $590.6 million in the first half of 2025. The company reported a net income of $380.0 million for the six months, up from $283.3 million in the same period last year. This growth can be attributed to the successful commercialization of ENHANZE partner products, particularly VYVGART Hytrulo and DARZALEX SC, which have gained traction in various markets.
Strategically, Halozyme has expanded its portfolio through acquisitions and collaborations. The company completed the acquisition of Elektrofi, Inc. in November 2025, enhancing its drug delivery technology offerings. Additionally, Halozyme has entered into several new collaboration agreements, including a significant partnership with Incyte to develop subcutaneous formulations of a monoclonal antibody, and agreements with GSK and Oruka for various oncology targets. These collaborations are expected to generate future milestone payments and royalties, further bolstering the company's revenue streams.
Operationally, Halozyme has seen an increase in its customer base and product adoption rates. The company reported a total of 10 commercial products generating royalties, with significant contributions from recent launches. The total cash and cash equivalents as of June 30, 2026, stood at $163.1 million, up from $133.8 million at the end of 2025. The company also reported a total employee headcount of 1,200, reflecting its growth and expansion efforts.
Looking ahead, Halozyme anticipates continued revenue growth driven by the increasing sales of ENHANZE partner products and the successful integration of its recent acquisitions. The company expects to leverage its expanded product portfolio and strategic partnerships to enhance its market position and drive future profitability. With a robust pipeline and a strong financial foundation, Halozyme is well-positioned to capitalize on emerging opportunities in the biopharmaceutical sector.
About HALOZYME THERAPEUTICS, INC.
Halozyme Therapeutics, Inc. develops innovative drug delivery and auto-injector technologies, primarily utilizing its ENHANZE platform with proprietary enzyme rHuPH20. It licenses its technology to biopharmaceutical partners for subcutaneous formulations, enhancing drug absorption and patient convenience. The company also markets proprietary products like Hylenex and XYOSTED, supporting collaborations with major pharma firms to improve injectable therapies and expand treatment options globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov